Clinical distribution and drug resistance analysis of carbapenem-resistant Pseudomonas aeruginosa from 2018 to 2022
10.3969/j.issn.1673-9701.2024.16.017
- VernacularTitle:2018-2022年耐碳青霉烯类铜绿假单胞菌临床分布及耐药分析
- Author:
Xiaofen HUANG
1
;
Yingying CAI
Author Information
1. 浙江省台州医院检验科,浙江临海 317000;台州恩泽医疗中心(集团)恩泽医院检验科,浙江台州 318050
- Keywords:
Carbapenem-resistant Pseudomonas aeruginosa;
Drug resistance rate;
Clinical distribution;
Antibacterial drug
- From:
China Modern Doctor
2024;62(16):70-73
- CountryChina
- Language:Chinese
-
Abstract:
Objective The clinical distribution characteristics and drug resistance of carbapenem-resistant Pseudomonas aeruginosa(CRPA)were analyzed to provide reference for clinical anti-infection treatment.Methods The data of hospitalized patients with Pseudomonas aeruginosa(PA)cultured and isolated from Enze Hospital,Taizhou Enze Medical Center(Group)from January 2018 to December 2022 were retrospectively analyzed,and the clinical departments,specimen types,patient ages and sensitivity to commonly used antibiotics for CRPA strains were statistically analyzed.Results A total of 1660 strains of PA were collected,of which 314 strains(18.92%)were CRPA.The detection rate of CRPA strains was the highest in 2018.The detection departments were mainly intensive medicine,respiratory and critical care medicine.The specimen types were mainly sputum.The age of patients was mainly between 61-80 years old.According to the drug sensitivity,there were small fluctuations in the resistance rates of CRPA strains to common antibacterial drugs.The resistance rate of piperacillin was lower than 40%,while the resistance rate of ticarcillin/clavulanate was consistently higher than 50%.The resistance rates of aminoglycosides and piperacillin/tazobactam were lower than 15%.Conclusion From 2018 to 2022,the detection rate of CRPA strains decreased first and then increased.The resistance rate of piperacillin/tazobactam was lower than 15%in past 5 years,so it can be preferred for clinical empirical treatment.
